Gangloff Scott A.
SEC insider (Form 3/4/5 filer). CIK 0001663253. Chief Technology Officer at Akero Therapeutics, Inc. (AKRO). 6 reported Form 4/5 transactions since Sep 2024; latest on Dec 9, 2025. Located in SOUTH SAN FRANCISCO, CA.
Companies Gangloff Scott A. has filed insider reports for
- Akero Therapeutics, Inc. (AKRO): Officer, Chief Technology Officer
Gangloff Scott A.
CIK: 0001663253
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (16.7%)
Position reduction
Option Exercises (M)1 (16.7%)
Derivative conversions
Awards (A)2 (33.3%)
Compensation grants
Other (G, F, J, C, D, …)2 (33.3%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AKRO
Akero Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Dec 9, 2025AKRO
Akero Therapeutics, Inc.
DispositionDirect5.1K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
DispositionDirect21.3K shares- - Aug 15, 2025AKRO
Akero Therapeutics, Inc.
ExerciseDirect2.6K shares at avg. $19.62$51K - Jun 30, 2025AKRO
Akero Therapeutics, Inc.
AwardDirect299 shares at avg. $23.87$7K - Jun 18, 2025AKRO
Akero Therapeutics, Inc.
SaleDirect848 shares at avg. $54.84$47K - Dec 16, 2024AKRO
Akero Therapeutics, Inc.
AwardDirect24.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | Disposition | 5,088 | - | - | Direct |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | Disposition | 21,263 | - | - | Direct |
| Aug 15, 2025 | AKRO Akero Therapeutics, Inc. | Exercise | 2,600 | $19.62 | $51,012 | Direct |
| Jun 30, 2025 | AKRO Akero Therapeutics, Inc. | Award | 299 | $23.87 | $7,137 | Direct |
| Jun 18, 2025 | AKRO Akero Therapeutics, Inc. | Sale | 848 | $54.84 | $46,504 | Direct |
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | Award | 24,300 | - | $0 | Direct |
1-6 of 6 transactions